Eugene Schneider
EVP, Chf Clinical Develop Ofcr at Ionis Pharmaceuticals Inc (IONS) since December 2020
Eugene Schneider has filed 27 insider reports with the SEC since January 2021, as EVP and chf Clinical Develop Ofcr at Ionis Pharmaceuticals Inc (IONS). In the last 12 months Eugene Schneider sold $3.74M of stock on the open market. In the latest filing, on June 30, 2026, Eugene Schneider sold 26,000 shares of Ionis Pharmaceuticals Inc (IONS) for $2.11M at an average of $81.05.
- Filings
- 27
- Companies
- 1
- Bought on market
- None
- Sold on market
- $8.05M
Companies where Eugene Schneider is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| EVP, Chf Clinical Develop Ofcrsince December 2020 | 77,114 | $8.05M | $26.58 | Jun 30, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 26, 2026-$2.11MIONSEVP, Chf Clinical Develop Ofcr Schneider Eugene exercised 26,000 shares at a strike of $60.89 and sold $2,107,196 worth of shares (26,000 units at $81.05) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Mar 19, 2026-$412KIONSSEC Form 4 filed by Schneider EugeneForm 4Open-market sale10b5-1 plan
- Jan 30, 2026-$516KIONSEVP, Chf Clinical Develop Ofcr Schneider Eugene was granted 11,991 shares and sold $515,630 worth of shares (6,179 units at $83.45), increasing direct ownership by 9% to 69,702 unitsForm 4Grant or awardOpen-market sale
- Jan 16, 2026-$703KIONSEVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 21,685 shares and sold $703,138 worth of shares (9,302 units at $75.59), increasing direct ownership by 24% to 63,890 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale
- Jan 2, 2026IONSSEC Form 4 filed by EVP, Chf Clinical Develop Ofcr Schneider EugeneForm 4Grant or award
- Sep 3, 2025-$1.2MIONSEVP, Chf Clinical Develop Ofcr Schneider Eugene exercised 19,658 shares at a strike of $53.77 and sold $1,195,421 worth of shares (19,658 units at $60.81)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Aug 4, 2025-$409KIONSEVP, Chf Clinical Develop Ofcr Schneider Eugene sold $408,701 worth of shares (9,549 units at $42.80), decreasing direct ownership by 16% to 51,507 unitsForm 4Open-market sale10b5-1 plan
- Jan 31, 2025-$47.8KIONSEVP, Chf Clinical Develop Ofcr Schneider Eugene was granted 4,032 shares and sold $47,780 worth of shares (1,484 units at $32.20), increasing direct ownership by 4% to 61,056 unitsForm 4Grant or awardOpen-market sale
- Jan 16, 2025-$214KIONSEVP, Chf Clinical Develop Ofcr Schneider Eugene converted options into 17,372 shares and sold $213,889 worth of shares (6,523 units at $32.79), increasing direct ownership by 23% to 58,508 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale
- Jan 2, 2025IONSSEC Form 4 filed by EVP, Chf Clinical Develop Ofcr Schneider EugeneForm 4Grant or award
- Feb 2, 2024-$104KIONSAmendment: EVP, Chf Clinical Develop Ofcr Schneider Eugene sold $104,437 worth of shares (2,106 units at $49.59), decreasing direct ownership by 4% to 47,659 unitsForm 4Open-market sale
- Feb 2, 2024-$103KIONSSchneider Eugene was granted 4,033 shares and sold $102,701 worth of shares (2,071 units at $49.59), increasing direct ownership by 4% to 49,812 unitsForm 4Grant or awardOpen-market sale
- Jan 17, 2024-$276KIONSSchneider Eugene converted options into 15,162 shares and sold $276,386 worth of shares (5,482 units at $50.42), increasing direct ownership by 25% to 47,850 unitsForm 4Exercise or conversion of a derivativeOpen-market sale
- Jan 15, 2024-$428KIONSSchneider Eugene exercised 8,000 shares at a strike of $32.60 and sold $427,999 worth of shares (8,000 units at $53.50)Form 4Grant or awardExercise or conversion of a derivativeOpen-market sale
- Jan 2, 2024IONSSEC Form 4 filed by Schneider EugeneForm 4Grant or award
- Dec 26, 2023-$1.29MIONSSchneider Eugene exercised 25,000 shares at a strike of $47.34 and sold $1,286,575 worth of shares (25,000 units at $51.46)Form 4Exercise or conversion of a derivativeOpen-market sale
- Dec 27, 2020IONSSEC Form 3: New insider Schneider Eugene claimed ownership of 13,224 shares (Amendment)Form 3New insider
- Feb 6, 2023-$57.5KIONSSEC Form 4: Schneider Eugene was granted 4,033 shares and sold $57,464 worth of shares (1,413 units at $40.67), increasing direct ownership by 12% to 24,946 unitsForm 4Grant or awardOpen-market sale
- Jan 18, 2023-$188KIONSSEC Form 4: Schneider Eugene converted options into 13,046 shares and sold $188,052 worth of shares (4,752 units at $39.57), increasing direct ownership by 59% to 22,326 units (withholding tax)Form 4Exercise or conversion of a derivativeOpen-market sale
- Jan 15, 2023IONSSEC Form 4 filed by Schneider EugeneForm 4Grant or award
- Jan 3, 2023IONSSEC Form 4 filed by Schneider EugeneForm 4Grant or award
- Oct 17, 2022IONSSEC Form 4: Schneider Eugene converted options into 416 shares and covered exercise/tax liability with 144 shares, increasing direct ownership by 2% to 14,032 units (for withholding tax)Form 4Shares withheld for taxes or exercise priceExercise or conversion of a derivative
- Jan 18, 2022IONSSEC Form 4: Schneider Eugene converted options into 10,400 shares and covered exercise/tax liability with 3,815 shares, increasing direct ownership by 92% to 13,760 units (tax liability)Form 4Shares withheld for taxes or exercise priceExercise or conversion of a derivative
- Jan 15, 2022IONSSEC Form 4 filed by Schneider EugeneForm 4Grant or award
- Jan 3, 2022IONSSEC Form 4 filed by Schneider EugeneForm 4Grant or award
- Oct 15, 2021IONSSEC Form 4: Schneider Eugene covered exercise/tax liability with 145 shares and converted options into 417 shares, increasing direct ownership by 4% to 7,175 units to satisfy withholding obligationForm 4Shares withheld for taxes or exercise priceExercise or conversion of a derivative
- Jan 15, 2021IONSSEC Form 4: Eugene Schneider exercised 7,503 units of Common Stock at a strike of $0.00 and disposed of $166,559 worth of Common Stock (2,718 units at $61.28), increasing ownership by 226% to 6,903 unitsForm 4Grant or awardShares withheld for taxes or exercise priceExercise or conversion of a derivative
Compare Eugene Schneider with
- Eugene Schneider vs Michael R Hayden1 shared
- Eugene Schneider vs C Frank Bennett1 shared
- Eugene Schneider vs Brett P Monia1 shared
- Eugene Schneider vs Patrick R. O'Neil1 shared
- Eugene Schneider vs Brian Birchler1 shared
- Eugene Schneider vs Peter N Reikes1 shared
Other insiders at the same companies
- Michael R HaydenIONS
- C Frank BennettIONS
- Patrick R. O'NeilIONS
- Brett P MoniaIONS
- Brian BirchlerIONS
- Peter N ReikesIONS
- Ludwig HantsonIONS
- Joan E HermanIONS
- Spencer R BerthelsenIONS
- Allene M. DiazIONS
- Holly B. KordasiewiczIONS
- Michael J. YangIONS
- Joseph LoscalzoIONS
- Joseph Klein IIIIONS
- Joseph BaroldiIONS
- Eric SwayzeIONS
Questions about Eugene Schneider
- What is Eugene Schneider's role at Ionis Pharmaceuticals Inc?
- Eugene Schneider reports to the SEC as EVP and chf Clinical Develop Ofcr at Ionis Pharmaceuticals Inc (IONS), according to the latest filing on June 30, 2026.
- How many shares does Eugene Schneider own?
- After the latest filing that states it, Eugene Schneider directly owned 77,114 shares of Ionis Pharmaceuticals Inc (IONS). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Eugene Schneider bought or sold stock recently?
- The most recent open-market sale was on June 26, 2026: sold 26,000 shares of Ionis Pharmaceuticals Inc (IONS) for $2.11M at an average of $81.05.
- How do I get alerts when Eugene Schneider files?
- Follow Eugene Schneider on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Eugene Schneider (SEC CIK 0001838539). Totals count each trade once, skipping amendments whose original is on file, from Jan 20, 2021 on. View on SEC EDGAR · Get this as JSON